Market Cap 10.04M
Revenue (ttm) 0.00
Net Income (ttm) -13.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 115,300
Avg Vol 66,822
Day's Range N/A - N/A
Shares Out 2.87M
Stochastic %K 30%
Beta 1.59
Analysts Strong Sell
Price Target $27.67

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005...

Industry: Biotechnology
Sector: Healthcare
Phone: 904 300 0701
Address:
822 A1A North, Suite 306, Ponte Vedra, United States
OnTheBalance
OnTheBalance Jun. 21 at 2:56 AM
$CVKD Stop Spamming other boards... first sign of a liquidity seeking SCAM
0 · Reply
WallStreetSignals
WallStreetSignals Jun. 19 at 8:50 AM
$CVKD intends to file for #FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki Disease. https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html #TheBullRunShow #CVKD #CadrenalTherapeutics #FDA #RarePediatricDisease #KawasakiDisease #Tecarfarin #Biotech #HealthcareStocks #BiotechStocks #NASDAQ #HealthcareInvesting #BiotechStocks #PennyStocks #StockMarket #GrowthStocks #Investing #SmallCapStocks #EmergingBiotech #HealthcareStocks #LifeSciences #ShareholderValue #MedicalBreakthrough 🚀📈
0 · Reply
stockwito
stockwito Jun. 18 at 11:31 PM
$CVKD how does this stock perform given the news?
0 · Reply
BioTuesdays
BioTuesdays Jun. 18 at 8:50 PM
$CVKD announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop coronary artery aneurysms (CAAs) and require chronic oral anticoagulation. https://biotuesdays.com/2026/06/18/cadrenal-plans-rpdd-request-for-tecarfarin-in-kd/
0 · Reply
EfamhS
EfamhS Jun. 18 at 3:50 PM
$CVKD https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html
0 · Reply
MikeTechnician
MikeTechnician Jun. 18 at 1:54 PM
$CVKD News Out - ladies and Gentlemen #stocktrading #biotech Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Diseasehttps://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html
0 · Reply
WallStreetSignals
WallStreetSignals Jun. 18 at 1:39 PM
$CVKD #BreakingNews | Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) intends to seek Rare Pediatric Disease Designation from the FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms. https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-to-file-for-fda-rare-pediatric-disease-da01dfll2sok.html #TheBullRunShow #BreakingNews #CVKD #RarePediatricDisease #FDA #KawasakiDisease #CoronaryAneurysms #PharmaceuticalNews
0 · Reply
DARKP00L
DARKP00L Jun. 18 at 1:19 PM
$CVKD 09:07 on Jun. 18 2026 Cadrenal Therapeutics Plans To Submit An FDA Rare Pediatric Disease Designation Request For Tecarfarin As A Treatment For Pediatric Patients With Kawasaki Disease And Coronary Artery Aneurysms Who Need Chronic Oral Anticoagulation #tradeideas
0 · Reply
focafoca99
focafoca99 Jun. 18 at 1:12 PM
$CVKD submitted a press release announcing plans to seek Rare Pediatric Disease Designation for tecarfarin to treat Kawasaki disease.
0 · Reply
MikeTechnician
MikeTechnician Jun. 17 at 6:59 PM
$CVKD Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 ⬇️
0 · Reply
Latest News on CVKD
Cadrenal Therapeutics to initiate CAD-1005 trial

2026-06-15T13:15:54.000Z - 5 days ago

Cadrenal Therapeutics to initiate CAD-1005 trial


Cadrenal Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Cadrenal Therapeutics Quarterly report: Q1 2026


Cadrenal Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Cadrenal Therapeutics Earnings release: Q1 2026


Cadrenal Therapeutics Slides: Investor presentation

May 4, 2026, 7:00 AM EDT - 6 weeks ago

Cadrenal Therapeutics Slides: Investor presentation


Cadrenal Therapeutics Inc trading resumes

2026-04-01T19:35:16.000Z - 2 months ago

Cadrenal Therapeutics Inc trading resumes


Cadrenal Therapeutics Annual report: Q4 2025

Mar 31, 2026, 9:00 AM EDT - 2 months ago

Cadrenal Therapeutics Annual report: Q4 2025


Cadrenal Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 9:00 AM EDT - 2 months ago

Cadrenal Therapeutics Earnings release: Q4 2025


Cadrenal Therapeutics highlights research on 12-LOX inhibition

2026-03-12T12:21:38.000Z - 3 months ago

Cadrenal Therapeutics highlights research on 12-LOX inhibition


Cadrenal Therapeutics announces Phase 2 results for CAD-1005

2026-02-24T13:39:32.000Z - 4 months ago

Cadrenal Therapeutics announces Phase 2 results for CAD-1005


Cadrenal's Quiet Expansion Play Is Starting to Get Loud

Dec 12, 2025, 11:00 AM EST - 6 months ago

Cadrenal's Quiet Expansion Play Is Starting to Get Loud


Cadrenal Therapeutics Slides: Investor presentation

Dec 11, 2025, 7:00 AM EST - 6 months ago

Cadrenal Therapeutics Slides: Investor presentation


Cadrenal Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 9:00 AM EST - 7 months ago

Cadrenal Therapeutics Earnings release: Q3 2025


Cadrenal Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 9:00 AM EST - 7 months ago

Cadrenal Therapeutics Quarterly report: Q3 2025


Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)

2025-08-11T12:20:21.000Z - 11 months ago

Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)


Cadrenal Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Cadrenal Therapeutics Earnings release: Q2 2025


Cadrenal Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Cadrenal Therapeutics Quarterly report: Q2 2025


Cadrenal Therapeutics announces trial plans for tecarfarin

2025-08-05T10:25:11.000Z - 11 months ago

Cadrenal Therapeutics announces trial plans for tecarfarin


Cadrenal Therapeutics Proxy statement: Proxy Filing

Jul 31, 2025, 8:00 AM EDT - 11 months ago

Cadrenal Therapeutics Proxy statement: Proxy Filing


Cadrenal Therapeutics Proxy statement: Proxy Filing

Jul 31, 2025, 8:00 AM EDT - 11 months ago

Cadrenal Therapeutics Proxy statement: Proxy Filing


Cadrenal Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cadrenal Therapeutics Earnings release: Q1 2025


Cadrenal Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cadrenal Therapeutics Quarterly report: Q1 2025


Cadrenal Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Cadrenal Therapeutics Earnings release: Q4 2024


Cadrenal Therapeutics Annual report: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Cadrenal Therapeutics Annual report: Q4 2024


Cadrenal Therapeutics  teams with Abbott inTECH-LVAD trial

2025-03-04T13:21:36.000Z - 1 year ago

Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial

ABT


Cadrenal Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cadrenal Therapeutics Quarterly report: Q3 2024


Cadrenal Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Cadrenal Therapeutics Quarterly report: Q2 2024


Cadrenal Therapeutics Earnings release: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Cadrenal Therapeutics Earnings release: Q2 2024


OnTheBalance
OnTheBalance Jun. 21 at 2:56 AM
$CVKD Stop Spamming other boards... first sign of a liquidity seeking SCAM
0 · Reply
WallStreetSignals
WallStreetSignals Jun. 19 at 8:50 AM
$CVKD intends to file for #FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki Disease. https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html #TheBullRunShow #CVKD #CadrenalTherapeutics #FDA #RarePediatricDisease #KawasakiDisease #Tecarfarin #Biotech #HealthcareStocks #BiotechStocks #NASDAQ #HealthcareInvesting #BiotechStocks #PennyStocks #StockMarket #GrowthStocks #Investing #SmallCapStocks #EmergingBiotech #HealthcareStocks #LifeSciences #ShareholderValue #MedicalBreakthrough 🚀📈
0 · Reply
stockwito
stockwito Jun. 18 at 11:31 PM
$CVKD how does this stock perform given the news?
0 · Reply
BioTuesdays
BioTuesdays Jun. 18 at 8:50 PM
$CVKD announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop coronary artery aneurysms (CAAs) and require chronic oral anticoagulation. https://biotuesdays.com/2026/06/18/cadrenal-plans-rpdd-request-for-tecarfarin-in-kd/
0 · Reply
EfamhS
EfamhS Jun. 18 at 3:50 PM
$CVKD https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html
0 · Reply
MikeTechnician
MikeTechnician Jun. 18 at 1:54 PM
$CVKD News Out - ladies and Gentlemen #stocktrading #biotech Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Diseasehttps://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html
0 · Reply
WallStreetSignals
WallStreetSignals Jun. 18 at 1:39 PM
$CVKD #BreakingNews | Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) intends to seek Rare Pediatric Disease Designation from the FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms. https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-to-file-for-fda-rare-pediatric-disease-da01dfll2sok.html #TheBullRunShow #BreakingNews #CVKD #RarePediatricDisease #FDA #KawasakiDisease #CoronaryAneurysms #PharmaceuticalNews
0 · Reply
DARKP00L
DARKP00L Jun. 18 at 1:19 PM
$CVKD 09:07 on Jun. 18 2026 Cadrenal Therapeutics Plans To Submit An FDA Rare Pediatric Disease Designation Request For Tecarfarin As A Treatment For Pediatric Patients With Kawasaki Disease And Coronary Artery Aneurysms Who Need Chronic Oral Anticoagulation #tradeideas
0 · Reply
focafoca99
focafoca99 Jun. 18 at 1:12 PM
$CVKD submitted a press release announcing plans to seek Rare Pediatric Disease Designation for tecarfarin to treat Kawasaki disease.
0 · Reply
MikeTechnician
MikeTechnician Jun. 17 at 6:59 PM
$CVKD Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 ⬇️
0 · Reply
iQuicky
iQuicky Jun. 17 at 5:57 PM
$INDP $CVKD $ARTV $REPL $RCKT investing in their future!
0 · Reply
MikeTechnician
MikeTechnician Jun. 17 at 4:24 PM
💊 $CVKD #NASDAQ Cadrenal Therapeutics Advances CAD-1005 Multi-Indication Strategy https://www.youtube.com/watch?v=TXl0hf-BGNs
0 · Reply
MikeTechnician
MikeTechnician Jun. 17 at 1:33 PM
$CVKD Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-advances-multi-indication-123000241.html
0 · Reply
WallStreetSignals
WallStreetSignals Jun. 17 at 1:08 PM
$CVKD #PressRelease is launching a Phase 2a trial for Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKD) to assess the safety and effectiveness of CAD-1005. https://www.channelchek.com/news-channel/cadrenal-therapeutics-cvkd-phase-2a-trial-for-new-cad-1005-indication-announced #Cardiology #ClinicalTrial #KidneyHealth #PharmaResearch #CSAAKD
0 · Reply
MikeTechnician
MikeTechnician Jun. 17 at 11:30 AM
💊 $CVKD #NASDAQ Cadrenal Therapeutics Advances CAD-1005 Multi-Indication Strategy https://www.youtube.com/watch?v=TXl0hf-BGNs
0 · Reply
Cloudwatcher
Cloudwatcher Jun. 17 at 1:05 AM
$CVKD What happened with Tecafarin...Phase 3 ready in late 2024 that was supposed to happen by the end of 2025 ???
0 · Reply
EfamhS
EfamhS Jun. 16 at 5:24 AM
$CVKD https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-advances-multi-indication-123000241.html
0 · Reply
History101
History101 Jun. 15 at 9:18 PM
$CVKD I still do not own any shares. on 10/24/2025 price was $14.13, and on the day of the post below price was $6.93. Those are declines of 76% and 51% respectively. Just like $RVPH, CVKD will have to raise $$ at a MUCH lower stock price now. Perhaps CVKD should have raised at $14?? or even $6?? wow, just wow. At least I get to take advantage of the poor financial mgmt via a much lower cost basis if and when I do decide to get back in. GLTALs!!
3 · Reply
SuperGreenToday
SuperGreenToday Jun. 15 at 7:01 PM
0 · Reply
DARKP00L
DARKP00L Jun. 15 at 1:20 PM
$CVKD 08:35 on Jun. 15 2026 Cadrenal Therapeutics Plans To Initiate Phase 2a Proof-Of-Concept Clinical Trial Of CAD-1005, Being Studied To Prevent Acute Kidney Injury In High-Risk Patients Undergoing Cardiac Surgery #tradeideas
0 · Reply
STACKD0E
STACKD0E Jun. 15 at 12:42 PM
0 · Reply
EfamhS
EfamhS Jun. 4 at 9:14 PM
$CVKD https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-showcase-phase-3-130000080.html
0 · Reply